Cargando…
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response
We used next-generation sequencing to identify somatic alterations in multiple metastatic sites from an “exceptional responder” lung adenocarcinoma patient during his 7-yr course of ERBB2-directed therapies. The degree of heterogeneity was unprecedented, with ∼1% similarity between somatic alteratio...
Autores principales: | Biswas, Romi, Gao, Shaojian, Cultraro, Constance M., Maity, Tapan K., Venugopalan, Abhilash, Abdullaev, Zied, Shaytan, Alexey K., Carter, Corey A., Thomas, Anish, Rajan, Arun, Song, Young, Pitts, Stephanie, Chen, Kevin, Bass, Sara, Boland, Joseph, Hanada, Ken-Ichi, Chen, Jinqiu, Meltzer, Paul S., Panchenko, Anna R., Yang, James C., Pack, Svetlana, Giaccone, Giuseppe, Schrump, David S., Khan, Javed, Guha, Udayan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111000/ https://www.ncbi.nlm.nih.gov/pubmed/27900369 http://dx.doi.org/10.1101/mcs.a001263 |
Ejemplares similares
-
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of
Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic
Tumors
por: Roper, Nitin, et al.
Publicado: (2019) -
Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma
por: Qi, Yue A., et al.
Publicado: (2021) -
SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma
por: Venugopalan, Abhilash, et al.
Publicado: (2021) -
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance
por: Maity, Tapan K., et al.
Publicado: (2023) -
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma
por: Qi, Yue A., et al.
Publicado: (2021)